IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Mapping GPR88-Venus illuminates a novel role for GPR88 in sensory processing.Brain Struct Funct 2017-11-06.
Identification of cross talk between SUMOylation and ubiquitylation using a sequential peptide immunopurification approach.Nat Protoc 2017-11-01;12(11):2342-2358.
Study of Methylene Blue Ototoxicity in the Guinea Pig.J Clin Med Res 2017-11-01;9(11):900-906.
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.Immunol. Rev. 2017-11-01;280(1):165-174.
WD40 repeat domain proteins: a novel target class?Nat Rev Drug Discov 2017-11-01;16(11):773-786.
PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.Mol. Cancer Ther. 2017-11-01;16(11):2528-2542.
UBAP2L is amplified in a large subset of human lung adenocarcinoma and is critical for epithelial lung cell identity and tumor metastasis.FASEB J. 2017-11-01;31(11):5012-5018.
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.Nat Commun 2017-10-31;8(1):1211.
Evolution of AF6-RAS association and its implications in mixed-lineage leukemia.Nat Commun 2017-10-23;8(1):1099.